Where does Editas Medicine, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Editas Medicine, Inc. ranks #6,761 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Editas Medicine, Inc. hold?

Editas Medicine, Inc. holds 49 US utility patents granted between 2017 and 2025, spanning 11 technology areas.

What is Editas Medicine, Inc.'s Innovation Score?

Editas Medicine, Inc. has an Innovation Score of 51.7 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Editas Medicine, Inc.'s patent grant rate increasing or decreasing?

Editas Medicine, Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Editas Medicine, Inc.'s patents?

Editas Medicine, Inc.'s patents average 21.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Editas Medicine, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Editas Medicine, Inc.

Q: What technology areas does Editas Medicine, Inc. focus on?

Editas Medicine, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 47 patents, ranking #210 of 4,144 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 49 granted patents across 11 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Editas ranks #6,761 of 49,997 tracked US assignees by granted-patent volume, with 49 patents across 11 technology areas.

#6,761
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.7/100): 21.9
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6761 · US Corporation #6,761 · 49 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 49 grants
UPPER-Q #6,761/49,997
PHOTO-FINISH Elite Semiconductor…
CPC-FOCUS C12N · 11 areas
INNOV-PAR 51.7/100
CLAIMS-DENSE 21.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Elite Semiconductor Microelectronics Technology Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Editas’s 51.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.5 pts (26%) Velocity 13.3 pts (26%) Breadth 11.7 pts (23%) Claim depth 13.1 pts (25%)

Qualcomm Incorporated · highest

85
CAE · near

52
Vetco Gray Scandinav… · near

52
CrowdStrike · near

52
Editas Medicine · this assignee

52
Tokyo Visionary Optics · near

52
3D Lighting… · lowest

7

What this shows Editas's Innovation Score is 51.7/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Editas?

Each dot is one of Editas’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Editas’s own 21.9 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Editas vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Editas's grants concentrate

Editas Medicine, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 95.9% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (9 grants) versus a trough of 1 in 2017. By volume, Editas sits between Eternal Materials Co., Ltd. and Fidia Farmaceutici S.p.A..

Editas's three-year grant acceleration

Editas Medicine, Inc. shows 24 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Eternal Materials

49
Eurokera S N C

49
Evatec

49
Exmark Manufactur…

49
Elite Semiconduct…

49
Endress+Hauser Co…

49
Express Imaging S…

49
Fidia Farmaceutic…

49
Editas Medicine ◀

49

What this shows Editas holds 49 patents at rank #6,766, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Editas

By rank, the assignees closest to #6,766 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Editas's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Editas, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Editas ranks #210 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (52 here).

Tokyo Visionary Optics Co., Ltd. 52 CrowdStrike, Inc. 52 Vetco Gray Scandinavia AS 52 CAE Inc. 52

Editas's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Editas Medicine, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	2.0%
2018	3	6.1%
2019	4	8.2%
2020	1	2.0%
2021	7	14.3%
2022	9	18.4%
2023	8	16.3%
2024	7	14.3%
2025partial year	9	18.4%

Which technologies does Editas Medicine, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 47

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

C12Y - Enzymes 7

C07K - Peptides 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 5

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Editas Medicine, Inc.'s patent record in context - here's where to go next.

Editas Medicine, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 95.9% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #6,761 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Editas Medicine, Inc. against Eternal Materials Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.